Original Messa e From: Boris Nikolic To: harryfisch Cc: jeevacation <[email protected] <mailto:[email protected]» Sent: Sat, Nov 3, 2018 1:27 pm Subject: RE: Re: Thank you Harry! Again — great meeting you. I am still laughing re inherited STD. Finally I had chance to read your slide deck. VERU is indeed very interesting company — congrats! You have an interesting mix of Urology specialty drugs (which I see as a low risk) and Prostate cancer drugs. Unfortunately my fund (https://www.biomaticscapital.com/) is only focused (and restricted to investing) on private companies. Mid-end of the next year I am going to fundraise a crossover fund which would allow me to invest in both private and publicly listed companies; nevertheless, I am now unable to invest in companies such as VERU — despite how interesting they might be. I looked at a female condom. I think that PATH supported a number of related projects. https://www.path.oreartides/seven-secrets-of-the-female-condom/ <https://www.path.orearticles/seven-secrets-of- the-female-condomh As you might know BMGF is the main donor to PATH — this is why I mentioned it. Also BMGF founded several smaller grants (GCE) re female condoms https://www.gatesfoundation.org/Media- Center/Press-Releases/2014/06/GCE-Round-12 <https://www.gatesfoundation.org/Media-Center/Press- Releases/2014/06/GCE-Round-12> In addition, there were grants to Imperial College in London, HealthRock etc. All of these are relatively old grants that ended. My guess is that all female condom more mature projects transitioned to PATH. 3 EFTA_R1_01815395 EFTA02615627